Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP

Pharmacopsychiatry

Volumn 37, Issue SUPPL. 1, 2004, Pages

  Degner, D ^a   Grohmann, R ^b   Kropp, S ^c   Ruther E ^a   Bender, S ^d   Engel, R R ^b   Schmidt, L C ^e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ADR; Adverse drug reactions; Antidepressants; Drug surveillance; Hyponatremia; MAO I mirtazapine; Seizure; SIADH; SSRI; TCA; Venlafaxine

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ADVERSE DRUG REACTION; AGED; AGITATION; ARTICLE; CARDIOVASCULAR DISEASE; COLLAPSE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DELIRIUM; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GERMANY; GRAND MAL SEIZURE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SKIN DISEASE; SKIN EDEMA; SODIUM BLOOD LEVEL; URINARY TRACT DISEASE; URINE RETENTION; WEIGHT GAIN; AGE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; SEX RATIO;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE DISTRIBUTION; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEX DISTRIBUTION;

EID: 2442700128     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull 2002; 36 (Suppl 2): 123-132
2. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Brit Med J 1995; 310: 1433-1436
3. CPM P. Working Party on Efficacy of Medicinal Products: Note for Guidance Good Clinical Practice for Trials on Medicinal Products in the European Community. Pharm Ind 1990; 52: 1476-1504
4. Corrigan OP. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises. Soc Sci Med 2002; 55: 497-507
5. Grohmann R, Ströbel Ch, Rüther E, Dirschedl P, Helmchen H, Hippius H, Müller-Oerlinghausen B, Schmidt LG, Wolf B. Adverse psychic reactions to psychotropic drugs - a report from the AMÜP study. Pharmacopsychiatry 1993; 26: 84-93
6. Grohmann R, Rüther E, Engel RR, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program; methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32: 21-28
7. Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt LG. The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data. Pharmacopsychiatry 2004; 37 Suppl 1: S16-26
8. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Brit J Psychiatry 1997; 170; 120-127
9. Jick SS, Dean AD, Jick H. Antidepressants and suicide. Brit Med J 1995 28; 310: 215-218
10. Kirby D, Ames D. Hyponatremia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry 2001; 16: 484-493
11. Kropp S, Ziegenbein M, Grohmann R, Engel R, Degner D. Galactorrhea due to psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: S84-88
12. Masood GR, Karki SD, Patterson WR. Hyponatremia with venlafaxine. Ann Pharmacother 1998; 32: 49-51
13. Meynaar IA, Peeters AJ, Mulder AH, Ottervanger JP. Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors venlafaxine and paroxetine. Neth J Med 1997; 50: 243-245
14. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
15. Montgomery SA. Safety of mirtazapine: A review. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 37-45
16. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001; 16: 163-178
17. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 2002; 17 (Suppl 1): S37S41
18. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999; 60 (Suppl 20): 4-8
19. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289-299
20. Grohmann R, Engel R, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results. Pharmacopsychiatry 2004; 37 Suppl 1: S4-11
21. Schlienger RG, Klinik MH, Eggenberger C, Drewe J. Seizures associated with therapeutic doses of venlafaxine and trimipramine. Ann Pharmacother 2000; 34: 402-405
22. Schmid C, Grohmann R, Engel R, Rüther E, Kropp S. Cardiac adverse effects associated with psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: S65-69
23. Schmidt LG, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H, Schönhöfer PS. Adverse drug reactions of first and second generation antidepressants - a critical evaluation of drug surveillance data. Brit J Psychiatry 1986; 148: 38-43
24. Seidl L, Thornton GF, Smith JW. Studies on the epidemiology of adverse drug reaction. Bull Johns Hopkins Hosp J 1966; 119: 299-315
25. Settle EC. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998; 59 (Suppl 16): 25-30
26. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-713
27. Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig W-D, Wagner G, Müller-Oerlinghausen B, Möller H-J, Hippius H, Rüther E. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: S70-78
28. Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, Möller H-J, Hippius H, Rüther E. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37 Suppl 1: S54-64
29. Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 2002; 21: 2027-2204